Catalog No.
Product Name
Application
Product Information
Citations
-
Anti-inflammatory Agent
24-O-Acetyllycoclavanol is a triterpenoid compound that functions as an anti-inflammatory agent by selectively targeting the NF-κB and ERK1/2 signaling pathways. Its biological activity includes the inhibition of lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), leading to decreased production of inflammatory mediators like nitric oxide (NO), IL-1β, and IL-8. This compound is particularly relevant for research applications in the context of inflammatory bowel disease (IBD) and can be isolated from the ethyl acetate extract of Lycopodium clavatum. -
FAP Inhibitor
BR103354 is a selective inhibitor of fibroblast activation protein (FAP) with an IC50 of 14 nM against human FAP. It effectively restores levels of phosphorylated ERK and Glut1, reduces non-fasting blood glucose concentrations, and enhances glucose tolerance, while also decreasing hepatic triglyceride content. This compound demonstrates potential in alleviating hepatic steatosis and fibrosis, making it a valuable tool for research into type 2 diabetes and non-alcoholic steatohepatitis. -
Anti-inflammatory Agent
Anti-inflammatory agent 31 is a derivative of andrographolide that functions primarily by inhibiting NF-κB activation through the upstream blockade of the PI3K/Akt and ERK1/2 MAPK signaling pathways. This compound exhibits notable anti-inflammatory activity, promoting the recovery of intracellular glutathione (GSH) levels. Additionally, anti-inflammatory agent 31 demonstrates a protective effect on liver cells, making it a valuable tool for research applications in inflammation and hepatoprotection. -
Antioxidant/Anti-inflammatory/Anticancer Agent
Licoflavanone, a flavanone with antioxidant, anti-inflammatory, and anticancer properties, is isolated from the leaf extract of Glycyrrhiza glabra. It exerts its anticancer effects by downregulating the mTOR/PI3K/AKT signaling pathway, leading to inhibition of cancer cell proliferation, migration, and invasion. Additionally, Licoflavanone activates pro-apoptotic factors such as Bax and Bad, along with multiple caspase enzymes. Its anti-inflammatory activity involves reducing NF-κB nuclear translocation and decreasing the phosphorylation of p38, JNK, and ERK1/2, ultimately inhibiting pro-inflammatory cytokines, COX-2, and iNOS expression. This compound is utilized in research on nasopharyngeal carcinoma and its underlying mechanisms. -
Anti-inflammatory Agent
Centaureidin is an orally active anti-inflammatory agent derived from Bidens pilosa, exhibiting an EC50 of 0.9 μg/mL as an IFN-promoter. This compound activates the Rho signaling pathway, resulting in actin and tubulin disassembly, which leads to dendritic retraction and the formation of stress fibers in melanocytes. Centaureidin demonstrates potent inhibitory effects on tumor cell growth and has been shown to significantly reduce paw edema in murine models, highlighting its potential utility in inflammatory and anticancer research. -
Multiple Target PROTAC
GT19630 is a multiple target PROTAC designed to degrade c-MYC, CK1α, GSPT1, and IKZF1/2/3 proteins. This compound effectively targets and reduces the levels of these proteins in various tumor cell lines, making it a valuable tool for studying diseases characterized by high c-MYC expression, including cancer, cardiovascular disorders, cerebrovascular diseases, and viral infections. Researchers can utilize GT19630 to further investigate the therapeutic potential of protein degradation in relevant biological contexts. -
IKZF2/CK1α Molecule Glue
DEG-35 is a CRBN-dependent dual degrader targeting IKZF2 and CK1α, exhibiting DC50 values of 1.4 nM and 4.4 nM, respectively. This compound activates the p53 apoptosis pathway, highlighting its potential in promoting cell death. DEG-35 serves as a valuable tool for research focused on Acute Myeloid Leukemia (AML), providing insights into targeted degradation strategies for therapeutic applications. -
IKZF1/3 And CSNK1A1 Molecular Glue Degrader
MI-2-80 is a molecular glue degrader that specifically targets IKZF1 and IKZF3, as well as CSNK1A1. This compound facilitates the binding of these proteins to the cereblon (CRBN) E3 ubiquitin ligase, promoting their subsequent ubiquitination and proteasomal degradation. MI-2-80 is valuable for research applications focused on understanding the functional roles of IKZF proteins and their involvement in various pathologies, including hematological malignancies. -
Anti-inflammatory Agent
(7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one is an anti-inflammatory agent targeting hepatic stellate cells. With an IC50 of 25.2 μM against TGF-β-induced HSC-T6 cells, this compound is instrumental in studies related to liver fibrosis by inhibiting excessive cell proliferation. Isolated from the dried aerial parts of Penthorum chinense Pursh, it holds potential for research into liver fibrosis-related conditions. -
CTLA-4 Degrader
AN02 is a CTLA-4 degrader that demonstrates potent anti-cancer activity in ovarian cancer research. This compound inhibits cell proliferation, clonogenicity, migration, and invasion of ovarian cancer cells while upregulating the expression of antigen-presenting cells (APC). AN02 mediates CTLA-4 degradation through the SMAD4 pathway, significantly reducing tumor growth in small xenograft models and reversing the immune-suppressive tumor environment. Additionally, when used in combination with Ipilimumab, AN02 enhances therapeutic efficacy and inhibits epithelial-mesenchymal transition, making it a valuable tool for studying ovarian cancer. -
Bone Marrow Mesenchymal Stem Cell Inducer
Herpetin is an active lignan that functions as a bone marrow mesenchymal stem cell inducer. It activates the SDF-1/CXCR4 axis and the Wnt/β-catenin signaling pathway, promoting stem cell recruitment and differentiation. This compound is relevant for research applications focused on acute liver injury and related regenerative processes. -
Anti-IL-1β Antibody
Abdakibart is a humanized IgG4 monoclonal antibody that selectively targets IL-1β, a key cytokine involved in the inflammatory response. This reagent is particularly valuable for research applications related to inflammatory diseases, including type 2 diabetes. By inhibiting IL-1β, Abdakibart can help elucidate the pathways involved in inflammation and contribute to the development of novel therapeutic strategies. -
IL-17A Modulator
IL-17A modulator-3 is a selective modulator targeting IL-17A. This compound demonstrates effective inhibition of the IL-17A/A receptor complex with an IC50 value of less than 10 μM. It is suitable for research applications related to inflammation, cancer biology, and autoimmune disorders, providing valuable insights into these critical areas of study. -
Anti-IL-1β Antibody
SSGJ-613 is a fully human monoclonal antibody that targets interleukin-1 beta (IL-1β). This reagent is designed for the investigation of inflammatory conditions, particularly gouty arthritis, by inhibiting the activity of IL-1β, a key mediator in the inflammatory response. Its application extends to research focused on understanding the role of IL-1β in various diseases and therapeutic development. -
IL-17 modulator
IL-17 modulator 6 is a potent inhibitor of Interleukin 17 (IL-17) with a pIC50 of 9.1. This compound effectively modulates IL-17 signaling and is utilized in the study of inflammatory and autoimmune diseases. Researchers may employ IL-17 modulator 6 to explore therapeutic strategies targeting IL-17 pathways. -
STING Agonist
STING Agonist-50 is a potent oral STING agonist that activates the STING signaling pathway with an IC50 of 3.457 μM. It facilitates the phosphorylation of downstream proteins TBK1 and IRF3, leading to the enhanced expression of key cytokines such as IFN-β, CXCL10, and IL-6. This compound has demonstrated the ability to inhibit tumor growth in syngeneic mouse models, making it a valuable tool for research focused on colorectal cancer. -
Anti-inflammatory Agent
Anti-inflammatory Agent 58 is a potent inhibitor of IL-1β, demonstrating an IC50 of 1.08 μM. This compound effectively reduces pro-inflammatory gene expression, limits protein secretion, and inhibits NF-κB phosphorylation. It is suitable for research applications focused on inflammatory pathways and the modulation of immune responses. -
Anti-inflammatory Agent
Pseudoginsenoside RT4 is an orally active tetracyclic triterpenoid with notable anti-inflammatory properties. It effectively reduces the levels of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, while enhancing IL-10 levels. Additionally, Pseudoginsenoside RT4 modulates gut microbiota composition, making it a valuable reagent for research related to ulcerative colitis and other inflammatory conditions. Its multifaceted mechanism of action positions it as a significant tool in the study of anti-inflammatory pathways. -
Anti-inflammatory Agent
Anti-inflammatory agent 59 is a selective inhibitor of interleukin-1 beta (IL-1β) with an IC50 of 2.28 μM. This compound effectively reduces pro-inflammatory gene expression and protein secretion while inhibiting NF-κB phosphorylation. It serves as a valuable tool in the study of inflammatory pathways and may aid in the development of new therapeutic strategies for inflammatory diseases. -
Anti-inflammatory Agent
Acutissimalignan B is a bioactive compound recognized for its role as an anti-inflammatory agent. It effectively reduces the mRNA expression of key inflammatory cytokines, including inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Additionally, Acutissimalignan B inhibits the phosphorylation of IκBα and the nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) p65, thereby demonstrating potential utility in neuroinflammation research and related disease models. -
Anti-inflammatory Agent
Linderaspirone A is a natural compound derived from the roots of Lindera aggregate that functions as an anti-inflammatory agent. It exhibits significant inhibitory effects on the production of pro-inflammatory mediators, including prostaglandin E2 (PGE2), TNF-α, and IL-6. This compound can be utilized in research applications focused on understanding the mechanisms of inflammation and developing therapeutic strategies for inflammatory diseases. -
PIKfyve Inhibitor
AS2677131 is a potent and orally active inhibitor of PIKfyve, targeting the PIKfyve-c-Rel signaling pathway. It effectively inhibits the production of pro-inflammatory cytokines, including IL-12p40, IL-6, and IL-1β, by selectively blocking the DNA-binding activity of c-Rel to their respective promoters. Additionally, AS2677131 reduces MHC class II expression on B cells. This compound is valuable for research in the fields of inflammation and immunology, particularly in studies related to arthritis. -
IL-2 Fusion Protein
Lecomkafusp alfa is an IL-2 fusion protein designed to enhance immunomodulatory activity. It consists of human IL-2 linked via a protease-cleavable peptide to a humanized single-domain VHH fragment that targets albumin. This compound demonstrates significant antineoplastic properties, making it a valuable tool in cancer immunotherapy research and the exploration of novel therapeutic strategies. -
Anti-IL-17A Antibody
HB-0017 is a humanized IgG1κ monoclonal antibody that specifically targets interleukin-17A (IL-17A). This antibody effectively inhibits IL-6 secretion induced by IL-17A with an IC50 value of 2.09 nM. HB-0017 has demonstrated significant efficacy in reducing ear thickness in a psoriasis-like mouse model induced by Imiquimod, as well as alleviating inflammation in models of IL-17A-induced arthritis and air pouch inflammation. -
Anti-IL-17A Antibody
Velvakiment is a humanized VHH nanobody that specifically targets interleukin-17A (IL-17A). This antibody is valuable for investigating autoimmune diseases, including multiple sclerosis and rheumatoid arthritis, by elucidating the role of IL-17A in inflammatory pathways. Its specificity and affinity facilitate advanced research on therapeutic interventions aimed at modulating IL-17A activity in various disease contexts. -
Anti-IL-17RB Antibody
Ponumkibart is a humanized IgG4κ antibody specifically designed to target the interleukin-17 receptor B (IL-17RB). This antibody serves as a critical tool for investigating the role of IL-17 signaling in various pathologies, including autoimmune diseases and inflammatory conditions. Its application in research includes the study of immune response modulation and the development of therapeutic strategies targeting IL-17 pathways. -
Anti-IL-13 Antibody
Zumilokibart is a humanized IgG1κ antibody that specifically targets interleukin-13 (IL-13). This antibody is designed to inhibit the biological activity of IL-13, a cytokine implicated in various allergic and inflammatory diseases. It is suitable for research applications focused on asthma, allergic rhinitis, and other conditions where IL-13 plays a pivotal role in pathophysiology. -
IL-17 Modulator
IL-17 Modulator 5 is a potent inhibitor targeting interleukin-17 (IL-17) with an IC50 of 1 nM. This compound exhibits significant inhibition of IL-17 associated pathways, playing a critical role in inflammatory responses. It is applicable in research on autoimmune diseases and inflammatory disorders, facilitating investigations into therapeutic avenues for conditions such as psoriasis and rheumatoid arthritis. -
Anti-inflammatory Peptide
IIIM1 is an orally active anti-inflammatory peptide that functions by stimulating the proliferation of regulatory T cells and promoting the production of RA1. This molecule effectively ameliorates symptoms associated with experimental autoimmune encephalomyelitis (EAE) by regulating cytokine balance. IIIM1 is a valuable tool for research focused on multiple sclerosis (MS) and its underlying immunological mechanisms. -
IL-2/IL-2Rα Antagonist
Ro26-4550 TFA is a low micromolar antagonist of the interleukin-2 (IL-2) and IL-2 receptor alpha (IL-2Rα) interaction, exhibiting an IC50 value of 3 μM. This compound serves as a valuable tool for investigating the IL-2 signaling pathway, making it relevant for studies in immunology and cancer research. Its ability to inhibit IL-2 signaling can aid in the understanding of immune responses and the development of therapeutic strategies targeting IL-2 mediated pathways. -
IL-10 Fusion Protein
Vimekofusp is a recombinant IL-10 fusion protein that specifically targets IL10RA and IL10RB receptors. This agent exhibits potent immunomodulatory activity by enhancing anti-inflammatory responses and promoting regulatory T cell functions. It is primarily utilized in research applications focusing on autoimmune diseases, chronic inflammation, and therapeutic strategies aimed at modulating the immune system. -
IL-2 Fusion Protein
Efpixileukin alfa is a fusion protein consisting of a human IL-2 variant connected at the C-terminus to a human immunoglobulin G1 (IgG1) Fc fragment. This immunomodulator enhances T-cell proliferation and activation, making it valuable for therapeutic applications in cancer immunotherapy and autoimmune diseases. Research involving Efpixileukin alfa focuses on its potential to improve immune responses and its role in modulating the tumor microenvironment. -
IL-23 Inhibitor
IL-23 cyclic peptide inhibitor 105 targets the interleukin-23 (IL-23) pathway, serving as a specific inhibitor of this pro-inflammatory cytokine. It exhibits significant potential in modulating inflammatory responses associated with disorders such as inflammatory bowel disease (IBD). This compound is a valuable tool for researchers investigating the role of IL-23 in various inflammatory conditions and developing therapeutic strategies targeting IL-23 signaling. -
Anti-Inflammatory Agent
Dactyllactone A is an isoquinoline alkaloid derived from Dactylicapnos scandens that functions as a potent anti-inflammatory agent. It effectively inhibits the expression of pro-inflammatory cytokines such as IL-1β and prostaglandins, including PGE2. This compound is valuable for research applications focused on inflammatory pathways and the exploration of therapeutic interventions in inflammatory diseases. -
Anti-inflammatory Agent
Lithocholic amide-C2-N(didecane) is a derivative of lithocholic acid designed as an anti-inflammatory agent. This compound exhibits the ability to spontaneously form lipid nanoparticles in aqueous environments, facilitating skin penetration and targeting deeper dermal layers. It demonstrates significant anti-inflammatory activity against psoriasis-like chronic skin conditions by inhibiting keratinocyte proliferation, downregulating mRNA expression of the EphA2 receptor, and reducing serum levels of pro-inflammatory cytokines, including IL-1α, IL-1β, and IFN-γ, through modulation of the Th17/Th2 inflammatory pathway. This makes Lithocholic amide-C2-N(didecane) a valuable tool for researching inflammatory skin disorders. -
IL-17 Modulator
IL-17 Modulator 1 is a small molecule that selectively targets the IL-17 signaling pathway. This compound exhibits high efficacy in modulating IL-17 activity, making it valuable for studying inflammatory diseases. It is particularly relevant in research focusing on psoriasis, ankylosing spondylitis, and psoriatic arthritis, providing insights into mechanisms of disease prevention and treatment. -
Anti-Inflammatory Agent
Anti-inflammatory agent 102 is a selective inhibitor of the ASK1/p38 MAPKs/NF-κB signaling pathway, exerting notable anti-inflammatory effects. It significantly reduces the release of nitric oxide (NO), reactive oxygen species (ROS), and key inflammatory cytokines, including IL-6, TNF-α, and IL-1β. This compound is valuable for research applications focused on inflammatory diseases, particularly ulcerative colitis (UC). -
Anti-inflammatory/hepatoprotective Agent
Isostrictiniin is a polyphenolic compound derived from Nymphaea candida, functioning as an anti-inflammatory and hepatoprotective agent. It enhances the expression of Nrf2 and HO-1 while inhibiting Keap1, leading to the reduction of phosphorylation levels of key proteins such as JNK, ERK1/2, p38, IκBα, and NF-κB p65. Isostrictiniin effectively decreases pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, and PGE2, demonstrating protective effects against acute lung injury induced by LPS and acute alcoholic liver injury. Its multifaceted activities encompass anti-inflammatory, antioxidant, and anti-fibrotic properties, making it a valuable tool in biochemical research. -
Anti-inflammatory Agent
(E/Z)-3-Hydroxylicochalcone A is a flavonoid with potent anti-inflammatory properties, primarily derived from licorice (Glycyrrhiza inflata and Glycyrrhiza uralensis). This compound effectively inhibits lipid peroxidation in rat liver microsomes and has been shown to reduce the production of reactive oxygen species (ROS), nitric oxide (NO), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) induced by lipopolysaccharide (LPS). Its versatile biological activity makes (E/Z)-3-Hydroxylicochalcone A a valuable reagent for research into oxidative stress and inflammation-related pathways. -
IL-17 Inhibitor
IL-17-IN-4 is a potent IL-17 inhibitor with an IC50 of less than 0.1 μM, making it a valuable tool for investigating the role of IL-17 in inflammatory diseases. This compound can facilitate research aimed at understanding the mechanisms of inflammation and the therapeutic potential of IL-17 modulation in conditions such as rheumatoid arthritis and psoriasis. Its high potency enables effective studies of IL-17 signaling pathways in various biological contexts. -
IL-17 Modulator
IL-17 modulator 8 is an orally active modulator targeting interleukin-17 (IL-17). This compound significantly reduces pro-inflammatory cytokines such as IL-6 and IFN-γ, as well as edema. IL-17 modulator 8 is applicable in research focused on arthritis and related inflammatory diseases. -
IL-2/IL-2Rα Binding Antagonis
Ro26-4550 is a potent antagonist of IL-2/IL-2Rα binding, exhibiting an IC50 value of 3 μM. This compound is valuable for investigating the modulation of IL-2 signaling pathways, which play a critical role in T cell proliferation and immune response regulation. Research applications include studying autoimmune diseases, cancer immunotherapy, and potential therapeutic interventions targeting IL-2-mediated effects. -
NRF2 Activator
S217879 is a selective NRF2 activator that functions by disrupting the KEAP1-NRF2 interaction with a dissociation constant (Kd) of 4.15 nM. This compound activates the NRF2 pathway, leading to enhanced antioxidant responses. S217879 has demonstrated efficacy in ameliorating steatohepatitis and mitigating liver fibrosis. It is a valuable tool for research focused on metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis. -
STING Activator
c-(2'FdAMP-2'FdIMP) is a cyclic dinucleotide (CDN) that functions as a STING activator. It effectively stimulates STING-dependent signaling pathways, including IRF and NF-κB, leading to enhanced immune responses. This compound is valuable for research into STING-based immunotherapy applications, particularly in the context of cancer and infectious disease studies. -
Anti-inflammatory Agent
TNF-α/IL-1β/IL-6-IN-1 is an anti-inflammatory agent that targets pro-inflammatory cytokines. It effectively downregulates the expression of TNF-α, IL-1β, and IL-6, while also inhibiting reactive oxygen species (ROS) production. Additionally, TNF-α/IL-1β/IL-6-IN-1 enhances cholesterol efflux by upregulating ABCG1. This reagent is suitable for research focused on inflammatory and lipid metabolic diseases, including atherosclerosis. -
IL-1β Secretion Inhibitor
K-832 is an orally active inhibitor of IL-1β secretion, targeting the interleukin-1 pathway. This compound demonstrates significant biological activity by reducing inflammatory responses associated with autoimmune disorders. K-832 is applicable in the research of rheumatoid arthritis and other conditions linked to elevated IL-1β levels, making it a valuable tool for studying inflammation and immune response modulation. -
IL-17 Modulator
IL-17 Modulator 9 is an orally active inhibitor targeting the IL-17 pathway. This compound significantly reduces levels of pro-inflammatory cytokines such as IL-6 and IFN-γ while also diminishing edema. It serves as a valuable tool for studying various inflammatory conditions and exploring therapeutic interventions. -
Anti-inflammatory Agent
Olcorolimus is a derivative of Rapamycin that functions as an anti-inflammatory agent. It effectively reduces levels of IL-4 and IL-5, as well as the presence of eosinophils, neutrophils, and lymphocytes, while also inhibiting cellular fibronectin, lung epithelial cell proliferation, and mucus hypersecretion in Ovalbumin-sensitized BALB/c mice. This compound is valuable for research in the fields of inflammation and immunology, particularly for models related to asthma. -
Anti-Inflammatory Agent
Hedycoronen A is a potent anti-inflammatory agent targeting the inhibition of pro-inflammatory cytokines such as IL-6, IL-12 p40, and TNF-α. It demonstrates effective inhibitory activity in LPS-stimulated bone marrow-derived dendritic cells (BMDCs), with IC50 values of 9.1 μM, 5.6 μM, and 46.0 μM, respectively. This compound is isolated from the plant Hedychium coronarium and is valuable for research focused on inflammatory pathways and therapeutic interventions. -
Anti-IL-1βAntibody
Anflekitug is a CHO-expressed human antibody that specifically targets interleukin-1 beta (IL-1β). This monoclonal antibody features a huIgG1 heavy chain and a huκ light chain, exhibiting a predicted molecular weight of 145 kDa. Anflekitug is suitable for applications in inflammatory research, including studies of autoimmune diseases and cytokine signaling pathways. For isotype control experiments, human IgG1 kappa may be used as an appropriate reference.
